Agenus (NASDAQ:AGEN) Shares Down 5.7%

Agenus Inc (NASDAQ:AGEN) shares traded down 5.7% on Friday . The company traded as low as $2.79 and last traded at $2.79, 822,120 shares traded hands during trading. A decline of 35% from the average session volume of 1,256,868 shares. The stock had previously closed at $2.96.

Separately, BidaskClub lowered shares of Agenus from a “sell” rating to a “strong sell” rating in a report on Friday, July 26th.

The stock’s fifty day moving average is $2.58 and its two-hundred day moving average is $2.81. The firm has a market capitalization of $383.10 million, a price-to-earnings ratio of -1.94 and a beta of 1.86.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.05). The company had revenue of $15.72 million for the quarter, compared to analyst estimates of $5.37 million. As a group, sell-side analysts expect that Agenus Inc will post -1.04 EPS for the current year.

A number of hedge funds have recently made changes to their positions in AGEN. Bank of Montreal Can grew its holdings in Agenus by 443.8% during the 2nd quarter. Bank of Montreal Can now owns 10,675 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 8,712 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Agenus during the 2nd quarter worth $34,000. Cambridge Investment Research Advisors Inc. acquired a new position in Agenus during the 2nd quarter worth $40,000. Jefferies Group LLC acquired a new position in Agenus during the 2nd quarter worth $44,000. Finally, Panagora Asset Management Inc. grew its holdings in Agenus by 613.9% during the 2nd quarter. Panagora Asset Management Inc. now owns 15,256 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 13,119 shares in the last quarter. 34.31% of the stock is owned by institutional investors.

About Agenus (NASDAQ:AGEN)

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Recommended Story: Compound Interest and Why It Matters When Investing

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.